TOYOPEARL® MX-Trp-650M Mixed-Mode Resin - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

TOYOPEARL® MX-Trp-650M Mixed-Mode Resin


TOYOPEARL® MX-Trp-650M is a new multimodal cation exchange resin with unique selectivity and high recovery. It provides high protein binding capacities and tolerates high conductivity feedstocks.

TOYOPEARL® MX-Trp-650M is based on a rigid methacrylic polymer matrix, which provides excellent pressure/flow properties and allows high flow rates at large scale. Its ligand, the amino acid tryptophan, provides ionic and hydrophobic interactions. TOYOPEARL® MX-Trp-650M combines the selectivity options of mixed-mode chromatography with the binding capacity of modern ion exchange resins. This new mixed-mode resin is well-suited for intermediate and polishing steps, such as aggregate removal in antibody purification, and for the purification of targets that are difficult to purify using common purification platforms.

For more information visit the website www.tosohbioscience.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here